THE MODERN BIO / FULL DIRECTORY
Every option.
Clearly sorted.
Browse popular prescription pathways and high-interest peptides across metabolic health, hormones, performance, sexual wellness, prevention, sleep and longevity. Status labels separate established uses from off-label and unapproved options.
Educational content only. Inclusion does not mean endorsement, availability or eligibility.Metabolic health & weight
Established metabolic prescriptions alongside emerging options that need a more careful evidence check.
GLP-1–based medications
Semaglutide, tirzepatide and related options for defined diabetes or chronic weight-management indications.
Open guide →Mixed statusMetformin
A proven diabetes medication with an unresolved role as a general longevity drug.
Open guide →FDA-approved usesOther weight-management medications
Phentermine/topiramate, naltrexone/bupropion and orlistat offer non-GLP-1 pathways for selected patients.
Open guide →FDA-approved usesTesamorelin
An approved peptide for a narrow HIV-lipodystrophy indication—not general weight loss.
Open guide →Not FDA-approvedRetatrutide
A triple-agonist peptide still in clinical development and not approved for consumer use.
Open guide →Not FDA-approvedAOD-9604
A growth-hormone fragment marketed for fat loss without an approved indication or persuasive clinical outcome evidence.
Open guide →Hormones & fertility
Diagnosis-based options where symptoms, repeat testing, fertility goals and ongoing monitoring shape the decision.
Testosterone therapy
For properly confirmed testosterone deficiency with fertility and safety monitoring.
Open guide →PrescriptionMenopause hormone therapy
Individualized systemic or local treatment based on symptoms, timing and personal risk.
Open guide →Mixed statusClomiphene, enclomiphene & hCG
Male hormone and fertility pathways with different approvals, evidence and specialist uses.
Open guide →PrescriptionThyroid medication
Laboratory-guided replacement for confirmed thyroid disease—not a general energy or weight-loss tool.
Open guide →FDA-approved usesHuman growth hormone
Somatropin is legitimate replacement therapy for confirmed growth-hormone deficiency—not a routine anti-aging or bodybuilding drug.
Open guide →Performance, muscle & recovery
Popular recovery and growth-signaling compounds separated by human evidence, approved use and product-quality reality.
BPC-157
A heavily marketed recovery peptide with insufficient human evidence and no approved use.
Open guide →Not FDA-approvedTB-500
A synthetic thymosin-beta-4 fragment promoted for injury recovery without an FDA-approved drug or established human protocol.
Open guide →Not FDA-approvedCJC-1295
An unapproved growth-hormone signaling peptide with early human pharmacology but unproven performance outcomes.
Open guide →Not FDA-approvedIpamorelin
An unapproved growth-hormone secretagogue commonly marketed for recovery, sleep and body composition.
Open guide →Not FDA-approvedSermorelin
A growth-hormone-releasing peptide with historical approval and current compounded, off-label marketing context.
Open guide →FDA-approved usesMecasermin / IGF-1
Approved for a rare pediatric IGF-1 deficiency—not a safe stand-in for bodybuilding products such as IGF-1 LR3.
Open guide →Sexual wellness
Options for blood flow, erectile function and selected desire concerns after cardiovascular and medication screening.
PDE5 inhibitors
Sildenafil, tadalafil and related prescription options for appropriate erectile-dysfunction care.
Open guide →FDA-approved usesFemale desire medications
Flibanserin and bremelanotide have narrow HSDD indications and very different schedules, risks and eligibility rules.
Open guide →FDA-approved usesBremelanotide (PT-141)
An approved peptide for a narrow premenopausal HSDD indication—not a universal libido treatment.
Open guide →Mixed statusOxytocin
An established obstetric medication often marketed far beyond its approved clinical role.
Open guide →Not FDA-approvedKisspeptin-10
A reproductive-signaling peptide that remains investigational.
Open guide →Skin & hair
Evidence-based dermatology options separated from cosmetic marketing and unproven peptide claims.
Hair-loss medications
Topical minoxidil and prescription options such as finasteride, matched to the cause and pattern.
Open guide →Mixed statusTretinoin & spironolactone
Prescription skincare options for selected acne, pigment and photoaging concerns.
Open guide →Mixed statusGHK-Cu
A copper peptide used in cosmetic products with early, product-dependent human evidence.
Open guide →Not FDA-approvedMelanotan II
An unapproved tanning peptide with meaningful product-quality and safety concerns.
Open guide →Heart health & prevention
Mainstream prevention belongs in an optimization directory because controlling proven risk often matters more than adding another experimental compound.
Cholesterol-lowering medications
Statins, ezetimibe, PCSK9-directed therapies and other options matched to LDL/ApoB burden and overall risk.
Open guide →FDA-approved usesBlood-pressure medications
Evidence-based drug classes selected from repeated readings, kidney function, conditions, side effects and pregnancy context.
Open guide →FDA-approved usesGLP-1 cardiovascular-risk pathway
Selected incretin products carry cardiovascular indications for defined populations—not class-wide wellness claims.
Open guide →Mixed statusLow-dose aspirin
Useful for selected secondary-prevention settings, but routine primary-prevention use can create avoidable bleeding risk.
Open guide →Sleep, focus & cognition
Diagnosis-first options for insomnia or excessive sleepiness, alongside popular neuropeptides whose marketing exceeds the evidence.
Prescription sleep medications
Orexin antagonists and other insomnia medicines may fit selected patients after CBT-I, apnea risk and next-day safety are reviewed.
Open guide →Mixed statusModafinil / armodafinil
Wakefulness-promoting controlled medications for defined sleep disorders—not general-purpose nootropics.
Open guide →Not FDA-approvedSemax
A neuroactive peptide marketed for focus and cognition without an FDA-approved U.S. drug product.
Open guide →Not FDA-approvedSelank
An anxiolytic-style peptide with limited evidence and no FDA-approved U.S. indication.
Open guide →Not FDA-approvedDSIP
A sleep-branded peptide with uncertain identity-to-outcome evidence and no approved product.
Open guide →Longevity, immune & emerging
High-interest options where mechanisms, early research, approved uses and online marketing frequently get blurred together.
Low-dose naltrexone (LDN)
An off-label approach with condition-specific evidence and a critical opioid-interaction warning.
Open guide →Off-labelRapamycin
An approved immunosuppressant with intriguing biology but no proven healthy-longevity indication.
Open guide →Not FDA-approvedMOTS-c
A mitochondrial-derived peptide with intriguing biology but no established human treatment protocol or FDA-approved product.
Open guide →Not FDA-approvedEpitalon
A longevity-marketed peptide supported mainly by preclinical and difficult-to-verify evidence.
Open guide →Not FDA-approvedThymosin alpha-1
An immune-signaling peptide used in some countries, but not approved by FDA and limited by indication and product context.
Open guide →Not FDA-approvedKPV
An anti-inflammatory peptide fragment with mostly preclinical evidence and no approved human use.
Open guide →Not FDA-approvedLL-37
An antimicrobial host-defense peptide with experimental interest and meaningful inflammatory and product-quality uncertainty.
Open guide →NEED A QUICKER START?